Quanterix CEO Leaves Immediately For Another Healthcare Job — Its 2026 Outlook Stays In Place
Commercial chief Jim Gute took over as interim CEO while the board searches for a permanent leader.
Quanterix, which makes tools for detecting proteins in blood and tissue, lost President and CEO Everett Cunningham Wednesday when he resigned effective immediately, according to an SEC filing. The company kept its 2026 financial outlook in place and appointed Chief Commercial Officer Jim Gute as interim president and CEO.
Cunningham Heads To GeneDx
Cunningham also left Quanterix's board. Quanterix said he accepted another healthcare opportunity and that his departure stemmed from no disagreements about operations, financial disclosures, accounting or legal matters.
GeneDx, which provides genomic diagnostics for rare diseases, separately named Cunningham its incoming chief executive. His appointment takes effect on or before December 15, 2026.
Commercial Chief Takes The Interim Job
Gute will keep his commercial leadership role alongside the interim jobs. He joined in August 2026, and the board has begun a permanent CEO search covering candidates inside and outside Quanterix.
His experience includes leading General Screening at Exact Sciences as senior vice president and commercial manager, following his work as general manager of its Western Region. He previously spent 18 years at GE Healthcare, where his executive roles included president of the North Central Region.
Quanterix will pay Gute an annualized $750,000 salary during his interim tenure.
Diagnostics And Revenue Remain Priorities
Quanterix retained the outlook it gave on November 9. Board Chair Bill Donnelly said the company's focus under Gute would include “improving commercial execution, accelerating revenue growth and expanding our diagnostics position.”
Quanterix sells instruments, test kits and software to research laboratories, academic institutions, contract research organizations and biopharmaceutical companies worldwide. Its Simoa and Spatial Biology platforms measure proteins in fluids and map proteins and cells in tissue.
The business earns recurring revenue from consumables, test kits, service contracts and extended warranties. Its Accelerator Laboratory in Bedford, Massachusetts, also provides research services and clinical testing, including blood tests that help healthcare providers evaluate Alzheimer's disease and other neurological conditions.
Cunningham will remain available to help hand over his responsibilities through December 11, 2026, while Quanterix searches for its permanent leader.
Sources
- 8-K Filing — Quanterix Corp (QTRX) — SEC EDGAR
- Exhibit ex991-qtrxx20261118.htm — Quanterix Corp 8-K exhibit — SEC EDGAR
- Quanterix Announces Leadership Transition Plan — businesswire.com
- GeneDx Announces Leadership Transition — businesswire.com